Conference Call with Marksans Pharma Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Marksans Pharma announced Q2FY26 results Q2FY26 Financial Highlights: Operating revenue stood at Rs 720.4 crore, up by 12.2% YoY, attributed to strong traction in the US market, supported by new product launches across the digestive and pain management segments. Gross profit stood at Rs 411.8 crore, up by 7.4% YoY, with gross margin of 57.2%. EBITDA stood at Rs 144.5 crore., with a margin of 20.1%. EPS was at Rs 2.2. Other Highlights: Cash generated from operations at Rs 75.2 crore during H1FY26. Capex of Rs 73.2 crore incurred during H1FY26. Working capital cycle ~150 days for Q2FY26. Cash balance of Rs 666.5 crore as on 30th September 2025. Research & development (R&D;) spends at Rs 26.2 crore in H1FY26, 2.0% of consolidated revenue Mark Saldanha, Managing Director, said: “Q2FY26 has been a strong quarter for us, with revenues growing 16% sequentially, driven by robust demand across our key markets. The US region recorded solid growth, demonstrating resilience amid macro challenges, supported by stabilizing tariff conditions, timely order book execution, and meaningful traction from new product launches. The UK market also witnessed improved demand and delivered stable results despite continued pricing pressures. Our EBITDA and PAT grew 44% and 70% QoQ, reflecting the benefits of operating leverage. Looking ahead, we remain optimistic about sustaining this momentum into the second half of the year. Our strategic focus and operational discipline position us well to deliver resilient growth and long-term value for our stakeholders.” Result PDF
Pharmaceuticals company Marksans Pharma announced Q1FY26 results Operating revenue stood at Rs 620 crore, up by 5% YoY, driven mainly by growth in the US market from new product launches in the gastrointestinal, pain management, and digestive health segments. Gross profit stood at Rs 358.2 crore, up by 8.9% YoY, with a gross margin expansion of 209 bps YoY to 57.8%. Gross margin improved with the liquidation of higher-cost inventories and benefits from softening input costs. EBITDA stood at Rs 100.1 crore, with a margin of 16.1%. EPS was at Rs 1.3. Mark Saldanha, Managing Director, said: “While Q1FY26 was a seasonally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in the US markets and the easing of raw material costs. While EBITDA and net profit margins were impacted by ramp-up costs, a one-time ECL provision for the emerging market division, and forex adjustments, these are transient and do not affect the fundamental momentum of our business. We are already seeing encouraging early signs of demand recovery in key markets such as the US, the UK, and Australia. With the Goa facility integration nearing completion, we are now sharply focused on scaling capacity, enhancing operational efficiency, and unlocking synergies. Our execution discipline, combined with a robust pipeline and expanding market presence, positions us well to deliver sustainable, long-term value. We remain committed to driving growth, improving returns, and creating enduring value for our stakeholders in FY26 and beyond.” Result PDF
Conference Call with Marksans Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Marksans Pharma announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Operating revenue stood at Rs 708.5 crore., up by 26.5% YoY driven growth across key markets, led by US region Gross profit stood at Rs 383.2 crore., up by 32.1% YoY, with a gross margin expansion of 228 bps YoY to 54.1%. Growth is attributed to softening of raw material prices and a better product mix. EBITDA stood at Rs 125.8 crore. up by 14.7% YoY, with a margin of 17.8% EPS is at Rs 2.0, an incroreease of 15.7% FY25 Financial Highlights: Operating revenue stood at Rs 2,622.8 crore., up by 20.5% YoY driven by growth across all markets US business grew by 34.7% YoY UK & Europe grew by 9.2% YoY Australia & New Zealand grew by 15.5% YoY Gross profit came in at Rs 1,479.1 crore., up by 29.8% YoY, with a gross margin of 56.4% EBITDA stood at Rs 528.6 crore., up by 15.3%, with an EBITDA margin of 20.2% EPS grew by 21.3% YoY to Rs 8.4 Mark Saldanha, Managing Director of the Company said “We are pleased to announce another year of robust performance; we have achieved highest ever annual revenues and profits. In FY25, we witnessed strong performance across all our markets, the US market has been a key growth driver with 35% YoY increase in revenue. Our OTC segment’s performance is at all-time high, crossing Rs 2000 crore in revenue, a testament to our focus and execution on expanding the OTC product pipeline. Looking forward, we continue to strengthen our foundation by increasing the capacity and strengthening our product pipeline. We are optimistic about building on this momentum and create more value for our stakeholders in the coming years” Result PDF
Conference Call with Marksans Pharma Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.